Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Risk factors to consider for extended anticoagulant therapy: a review of guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions There was one evidence-based guideline identified that evaluated risks and benefits of extended duration anticoagulation. The guidelines state that decision to extend anticoagulation therapy beyond the standard three month treatment should consider the patients risk of recurrent VTE, major bleeding and their preferences. The primary individual risk factors for VTE recurrence that may warrant extended anticoagulation include the presence of active cancer, experiencing a second unprovoked VTE, or a first episode of unprovoked proximal deep vein thrombosis (DVT) or pulmonary embolism (PE). In patients with a high bleeding risk, the benefit of extended therapy may be outweighed by the increased risk of major bleeding. Indexing Status Subject indexing assigned by CRD MeSH Anticoagulantss; Risk Assessment; Risk Factors; Venous Thromboembolism Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000218 Date abstract record published 29/01/2014 |